Related references
Note: Only part of the references are listed.Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment
Fatih Gurler et al.
ANTI-CANCER DRUGS (2022)
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Paula Jimenez-Fonseca et al.
GASTRIC CANCER (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Salah-Eddin Al-Batran et al.
ONCOLOGIST (2020)
Analysis of Prognostic Factors and Design of Prognosis Model for Patients with Stage IV Gastric Cancer Following First-Line Palliative Chemotherapy
Qiyin Zhou et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Ari Joseph Rosenberg et al.
ONCOLOGIST (2019)
Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
Maren Knoedler et al.
BRITISH JOURNAL OF CANCER (2018)
Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer
Mengyao Liu et al.
ONCOTARGETS AND THERAPY (2018)
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer The AIO-FLOT3 Trial
Salah-Eddin Al-Batran et al.
JAMA ONCOLOGY (2017)
Chemotherapy for advanced gastric cancer
Anna Dorothea Wagner et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030
Melina Arnold et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
P. S. Hall et al.
BRITISH JOURNAL OF CANCER (2017)
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer
Jinwan Wang et al.
GASTRIC CANCER (2016)
Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Jifang Gong et al.
BMC CANCER (2016)
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Melanie Kripp et al.
GASTRIC CANCER (2014)
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data
Ulrich Ronellenfitsch et al.
EUROPEAN JOURNAL OF CANCER (2013)
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
Salah-Eddin Al-Batran et al.
EUROPEAN JOURNAL OF CANCER (2013)
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
Abeer Hussien Anter et al.
MEDICAL ONCOLOGY (2013)
Epidemiology and Risk Factors for Gastroesophageal Junction Tumors: Understanding the Rising Incidence of This Disease
Matthew F. Buas et al.
SEMINARS IN RADIATION ONCOLOGY (2013)
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
Marc Ychou et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
Christoph Schuhmacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
S. -E. Al-Batran et al.
ANNALS OF ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials
M. Trumper et al.
EUROPEAN JOURNAL OF CANCER (2006)
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PV1 5-FU) with epirubicin, cisplatin, and PV15-FU in advanced esophagogastric cancer
P Ross et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
